[Triple-gene therapy in Parkinson disease (ProSavin): toward a putaminal dopamine factory?].
Identifieur interne : 000621 ( PubMed/Corpus ); précédent : 000620; suivant : 000622[Triple-gene therapy in Parkinson disease (ProSavin): toward a putaminal dopamine factory?].
Auteurs : M. AnheimSource :
- Revue neurologique [ 0035-3787 ] ; 2014.
English descriptors
- KwdEn :
- Clinical Trials, Phase I as Topic (trends), Clinical Trials, Phase II as Topic (trends), Dopamine (metabolism), France, Genetic Therapy (methods), Genetic Vectors (administration & dosage), Glutamate Decarboxylase (administration & dosage), Glutamate Decarboxylase (genetics), Humans, Infusions, Intraventricular, Parkinson Disease (genetics), Parkinson Disease (metabolism), Parkinson Disease (therapy), Pilot Projects, Putamen (metabolism), Putamen (pathology), United Kingdom.
- MESH :
- chemical , administration & dosage : Glutamate Decarboxylase.
- chemical , genetics : Glutamate Decarboxylase.
- chemical , metabolism : Dopamine.
- administration & dosage : Genetic Vectors.
- genetics : Parkinson Disease.
- metabolism : Parkinson Disease, Putamen.
- methods : Genetic Therapy.
- pathology : Putamen.
- therapy : Parkinson Disease.
- trends : Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic.
- France, Humans, Infusions, Intraventricular, Pilot Projects, United Kingdom.
DOI: 10.1016/j.neurol.2014.02.002
PubMed: 24581302
Links to Exploration step
pubmed:24581302Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Triple-gene therapy in Parkinson disease (ProSavin): toward a putaminal dopamine factory?].</title>
<author><name sortKey="Anheim, M" sort="Anheim, M" uniqKey="Anheim M" first="M" last="Anheim">M. Anheim</name>
<affiliation><nlm:affiliation>Service de neurologie, unité des mouvements anormaux, Centre expert inter-régional de la maladie de Parkinson, hôpitaux universitaires de Strasbourg, 1, place de l'Hôpital, 67000 Strasbourg, France. Electronic address: mathieu.anheim@chru-strasbourg.fr.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="RBID">pubmed:24581302</idno>
<idno type="pmid">24581302</idno>
<idno type="doi">10.1016/j.neurol.2014.02.002</idno>
<idno type="wicri:Area/PubMed/Corpus">000621</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000621</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">[Triple-gene therapy in Parkinson disease (ProSavin): toward a putaminal dopamine factory?].</title>
<author><name sortKey="Anheim, M" sort="Anheim, M" uniqKey="Anheim M" first="M" last="Anheim">M. Anheim</name>
<affiliation><nlm:affiliation>Service de neurologie, unité des mouvements anormaux, Centre expert inter-régional de la maladie de Parkinson, hôpitaux universitaires de Strasbourg, 1, place de l'Hôpital, 67000 Strasbourg, France. Electronic address: mathieu.anheim@chru-strasbourg.fr.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Revue neurologique</title>
<idno type="ISSN">0035-3787</idno>
<imprint><date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Clinical Trials, Phase I as Topic (trends)</term>
<term>Clinical Trials, Phase II as Topic (trends)</term>
<term>Dopamine (metabolism)</term>
<term>France</term>
<term>Genetic Therapy (methods)</term>
<term>Genetic Vectors (administration & dosage)</term>
<term>Glutamate Decarboxylase (administration & dosage)</term>
<term>Glutamate Decarboxylase (genetics)</term>
<term>Humans</term>
<term>Infusions, Intraventricular</term>
<term>Parkinson Disease (genetics)</term>
<term>Parkinson Disease (metabolism)</term>
<term>Parkinson Disease (therapy)</term>
<term>Pilot Projects</term>
<term>Putamen (metabolism)</term>
<term>Putamen (pathology)</term>
<term>United Kingdom</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Glutamate Decarboxylase</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Glutamate Decarboxylase</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine</term>
</keywords>
<keywords scheme="MESH" qualifier="administration & dosage" xml:lang="en"><term>Genetic Vectors</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Parkinson Disease</term>
<term>Putamen</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Genetic Therapy</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Putamen</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Clinical Trials, Phase I as Topic</term>
<term>Clinical Trials, Phase II as Topic</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>France</term>
<term>Humans</term>
<term>Infusions, Intraventricular</term>
<term>Pilot Projects</term>
<term>United Kingdom</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24581302</PMID>
<DateCreated><Year>2014</Year>
<Month>03</Month>
<Day>03</Day>
</DateCreated>
<DateCompleted><Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<DateRevised><Year>2016</Year>
<Month>11</Month>
<Day>25</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0035-3787</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>170</Volume>
<Issue>2</Issue>
<PubDate><Year>2014</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
<Title>Revue neurologique</Title>
<ISOAbbreviation>Rev. Neurol. (Paris)</ISOAbbreviation>
</Journal>
<ArticleTitle>[Triple-gene therapy in Parkinson disease (ProSavin): toward a putaminal dopamine factory?].</ArticleTitle>
<Pagination><MedlinePgn>89-90</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neurol.2014.02.002</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0035-3787(14)00711-5</ELocationID>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Anheim</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Service de neurologie, unité des mouvements anormaux, Centre expert inter-régional de la maladie de Parkinson, hôpitaux universitaires de Strasbourg, 1, place de l'Hôpital, 67000 Strasbourg, France. Electronic address: mathieu.anheim@chru-strasbourg.fr.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>fre</Language>
<PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType>
</PublicationTypeList>
<VernacularTitle>La thérapie tri-génique dans la maladie de Parkinson (ProSavin): vers une usine à dopamine putaminale?</VernacularTitle>
</Article>
<MedlineJournalInfo><Country>France</Country>
<MedlineTA>Rev Neurol (Paris)</MedlineTA>
<NlmUniqueID>2984779R</NlmUniqueID>
<ISSNLinking>0035-3787</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>EC 4.1.1.15</RegistryNumber>
<NameOfSubstance UI="D005968">Glutamate Decarboxylase</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber>
<NameOfSubstance UI="D004298">Dopamine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D017321" MajorTopicYN="N">Clinical Trials, Phase I as Topic</DescriptorName>
<QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017322" MajorTopicYN="N">Clinical Trials, Phase II as Topic</DescriptorName>
<QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N">France</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015316" MajorTopicYN="N">Genetic Therapy</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005822" MajorTopicYN="N">Genetic Vectors</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005968" MajorTopicYN="N">Glutamate Decarboxylase</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D057967" MajorTopicYN="N">Infusions, Intraventricular</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011699" MajorTopicYN="N">Putamen</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N">United Kingdom</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year>
<Month>01</Month>
<Day>23</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2014</Year>
<Month>01</Month>
<Day>28</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2014</Year>
<Month>01</Month>
<Day>31</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2014</Year>
<Month>3</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2014</Year>
<Month>3</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2014</Year>
<Month>11</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">24581302</ArticleId>
<ArticleId IdType="pii">S0035-3787(14)00711-5</ArticleId>
<ArticleId IdType="doi">10.1016/j.neurol.2014.02.002</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000621 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000621 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:24581302 |texte= [Triple-gene therapy in Parkinson disease (ProSavin): toward a putaminal dopamine factory?]. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:24581302" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a ParkinsonFranceV1
![]() | This area was generated with Dilib version V0.6.29. | ![]() |